Literature DB >> 35599543

Commentary on Oeckl et al., "Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181".

Elizabeth Head1, Henrik Zetterberg2,3,4,5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35599543      PMCID： PMC9348592          DOI： 10.1002/ana.26414

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   11.274


× No keyword cloud information.
  19 in total

1.  Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease.

Authors:  Sarah B Martin; Amy L S Dowling; Joann Lianekhammy; Ira T Lott; Eric Doran; M Paul Murphy; Tina L Beckett; Frederick A Schmitt; Elizabeth Head
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

2.  Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease.

Authors:  C F Lippa; M L Schmidt; V M Lee; J Q Trojanowski
Journal:  Ann Neurol       Date:  1999-03       Impact factor: 10.422

3.  Excessive expression of synaptojanin in brains with Down syndrome.

Authors:  Yasuhiro Arai; Takeshi Ijuin; Tadanomi Takenawa; Laurence E Becker; Sachio Takashima
Journal:  Brain Dev       Date:  2002-03       Impact factor: 1.961

4.  Patterns of Mixed Pathologies in Down Syndrome.

Authors:  Shojiro Ichimata; Koji Yoshida; Naomi P Visanji; Anthony E Lang; Naoki Nishida; Gabor G Kovacs
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.472

5.  Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181.

Authors:  Patrick Oeckl; Olivia Wagemann; Steffen Halbgebauer; Sarah Anderl-Straub; Georg Nuebling; Catharina Prix; Sandra V Loosli; Elisabeth Wlasich; Adrian Danek; Petra Steinacker; Albert C Ludolph; Johannes Levin; Markus Otto
Journal:  Ann Neurol       Date:  2022-04-12       Impact factor: 10.422

Review 6.  Biofluid-based biomarkers for Alzheimer's disease-related pathologies: An update and synthesis of the literature.

Authors:  Henrik Zetterberg
Journal:  Alzheimers Dement       Date:  2022-02-25       Impact factor: 16.655

Review 7.  Dementia in Down syndrome: unique insights for Alzheimer disease research.

Authors:  Ira T Lott; Elizabeth Head
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

8.  Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome.

Authors:  Melissa E Petersen; Michael S Rafii; Fan Zhang; James Hall; David Julovich; Beau M Ances; Nicole Schupf; Sharon J Krinsky-McHale; Mark Mapstone; Wayne Silverman; Ira Lott; William Klunk; Elizabeth Head; Brad Christian; Tatiana Foroud; Florence Lai; H Diana Rosas; Shahid Zaman; Mei-Cheng Wang; Benjamin Tycko; Joseph H Lee; Benjamin Handen; Sigan Hartley; Juan Fortea; Sid O'Bryant
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

9.  Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study.

Authors:  Maria Carmona-Iragui; Daniel Alcolea; Isabel Barroeta; Laura Videla; Laia Muñoz; Kathyrn L Van Pelt; Frederick A Schmitt; Donita D Lightner; Lisa M Koehl; Gregory Jicha; Silvia Sacco; Clotilde Mircher; Sarah E Pape; Rosalyn Hithersay; Isabel C H Clare; Anthony J Holland; Georg Nübling; Johannes Levin; Shahid H Zaman; Andre Strydom; Anne-Sophie Rebillat; Elizabeth Head; Rafael Blesa; Alberto Lleó; Juan Fortea
Journal:  Lancet Neurol       Date:  2021-08       Impact factor: 59.935

10.  Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study.

Authors:  Concepcion Padilla; Victor Montal; Madeleine J Walpert; Young T Hong; Tim D Fryer; Jonathan P Coles; Franklin I Aigbirhio; Sigan L Hartley; Ann D Cohen; Dana L Tudorascu; Bradley T Christian; Benjamin L Handen; William E Klunk; Anthony J Holland; Shahid H Zaman
Journal:  Alzheimers Dement (Amst)       Date:  2022-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.